Acceleron Pharma (XLRN) Misses Q1 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acceleron Pharma Reports First Quarter 2017 Operational and Financial Results
May 8, 2017 7:00 AM EDT- Luspatercept MEDALIST and BELIEVE Phase 3 trials expected to complete enrollment in Q2 2017 -
- Presented results from ongoing Phase 2 trial with luspatercept at the 14th International Symposium on MDS -
- Announced plans to initiate luspatercept Phase 3 trial in first-line, lower-risk MDS in early 2018 -
- Announced plans to initiate ACE-083 Phase 2 study in Charcot-Marie-Tooth disease -
- Maintained strong balance sheet with $213.2 million in cash, cash equivalents and investments to fund projected operating requirements into the second... More
